Journal Pre-proof

Machine learning for precision dermatology: Advances, opportunities, and outlook

Ernest Y. Lee, MD, PhD, Nolan J. Maloney, MD, Kyle Cheng, MD, Daniel Q. Bach, MD, MPH

PII: S0190-9622(20)32161-7

DOI: https://doi.org/10.1016/j.jaad.2020.06.1019

Reference: YMJD 14918

To appear in: Journal of the American Academy of Dermatology

Received Date: 12 September 2019

Revised Date: 8 June 2020

Accepted Date: 26 June 2020

Please cite this article as: Lee EY, Maloney NJ, Cheng K, Bach DQ, Machine learning for precision dermatology: Advances, opportunities, and outlook, *Journal of the American Academy of Dermatology* (2020), doi: https://doi.org/10.1016/j.jaad.2020.06.1019.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.



Article Type: Research Letter

Title: Machine learning for precision dermatology: Advances, opportunities, and outlook

Ernest Y. Lee, MD, PhD^{1,2,3*}, Nolan J. Maloney MD², Kyle Cheng, MD², Daniel Q. Bach, MD, MPH²

¹ Department of Bioengineering, UCLA, Los Angeles, CA 90095, United States

² Division of Dermatology, Department of Medicine, UCLA, Los Angeles, CA 90095, United States

³ UCLA-Caltech Medical Scientist Training Program, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, United States

Corresponding Author:

Ernest Y. Lee, MD, PhD Email: ernest.lee@ucla.edu

Funding Sources: E.Y.L. acknowledges support from the UCLA-Caltech Medical Scientist Training Program (T32GM008042) and the Dermatology Scientist Training Program (T32AR071307) at UCLA, and an Early Career Research Grant from the National Psoriasis Foundation.

Conflicts of Interest: None

Reprint requests: Ernest Y. Lee, MD, PhD

Manuscript word count: 505 words References: 15 (25 supplemental references) Figures: 1 Supplementary figures: 0 Tables: 0 Supplementary tables: 1 (available at <u>http://dx.doi.org/10.17632/8w4dkfbdpk.1</u>)

Keywords: Machine learning, artificial intelligence, precision medicine, precision dermatology, biomarkers, diagnosis, treatment

To the editor:

With the explosion of "big data" in medicine driven by the advent of electronic medical records, next-generation sequencing and "multi-omics", and non-invasive imaging techniques, dermatology is a field at the precipice of an artificial intelligence (AI) revolution. Yet to the majority of clinicians, machine learning (ML) is a magical "black box" that is powerful but inaccessible. Here, we review the latest advances in machine learning applied to dermatological diagnosis and treatment and highlight key discoveries with translational potential. ML is an AI technique that focuses on designing machines (or computers) that mimic human pattern recognition and problem solving¹. With the rise of "big data" and "data science", machine

learning and artificial intelligence already impact our daily lives in innumerable ways. Comparatively, clinical medicine has been slower to integrate machine learning into daily practice². Machine learning has typically been considered a tool well outside of a typical clinician's purview. At the same time, there is now an enormous demand for high quality research that is advancing health care using ML and Al³. ML is a natural fit for translation into dermatology because dermatology is a specialty that is heavily reliant on visual evaluation and pattern recognition.

We searched the literature for high quality studies published within the last 5 years describing the latest advances in machine learning applied to precision dermatology (Supplementary Table 1). Since digital photography is so prevalent, many ML studies in dermatology focus on lesion image analysis⁴⁻⁷ and classification^{8,9}. However, we also find that ML is now also being applied to electronic medical records (EMR), patient laboratory data, and genomic data from next-generation sequencing to study the genetic basis of diseases, to identify associations between comorbidities, risk factors, and disease prognosis, and to design and predict responses to pharmacologic therapies (Supplementary Table 1). Applications span prediction of adverse drug reactions¹⁰ to responses to therapy in oncologic dermatology¹¹ and autoimmune and rheumatologic skin disease¹². Together, these landmark studies outline a promising generalized framework that leverages gene expression data and "multi-omics" for biomarker discovery in autoimmune skin diseases, and for biologics and immunotherapies in general (Figure 1A, B). The convergence of ML and next-generation sequencing represents a golden opportunity to advance precision dermatology, and multidisciplinary collaborations between machine learning experts, biologists, and dermatologists will be required to expand the scope of this research.

The promise of an AI revolution in dermatology also comes with an accompanying fear of "black boxes" and a concern for how this may impact patient care and patient perceptions of care. Similarly, there is a prevailing fear among physicians that machines will largely replace clinicians in dermatology, as well as in radiology and pathology¹³. It is our view that machine learning will not replace dermatologists¹⁴. Rather, these tools will enable dermatologists to provide a higher quality of care to their patients¹⁵. In fact, we believe that machine learning tools, such as downloadable local programs on personal computers, open-source online webservers, or mobile applications on smartphones, will be tightly integrated into the daily clinical practice of the dermatologist in the near future.

Figure 1: Machine learning for precision medicine. (A) Schematic demonstrating training and validation of a machine learning model from multimodal input patient data, such as clinical images, patient demographics, and "multi-omics". (B) Application of the machine learning model to choose individually-tailored therapies for specific disease states.

References

- 1. Hastie T, Tibshirani R, Friedman J. *The Elements of Statistical Learning*. New York, NY: Springer Science & Business Media; 2009. doi:10.1007/978-0-387-84858-7.
- 2. Rajkomar A, Dean J, Kohane I. Machine Learning in Medicine. *N Engl J Med*. 2019;380(14):1347-1358. doi:10.1056/NEJMra1814259.
- 3. Rivara FP, Fihn SD, Perlis RH. Advancing Health and Health Care Using Machine Learning: JAMA Network Open Call for Papers. *JAMA Netw Open*. 2018;1(8):e187176-e187176. doi:10.1001/jamanetworkopen.2018.7176.
- 4. Yap J, Yolland W, Tschandl P. Multimodal skin lesion classification using deep learning. *Exp Dermatol*. 2018;27(11):1261-1267. doi:10.1111/exd.13777.
- Tschandl P, Argenziano G, Razmara M, Yap J. Diagnostic accuracy of content-based dermatoscopic image retrieval with deep classification features. *Br J Dermatol*. 2018;141(1):1388–165. doi:10.1111/bjd.17189.
- 6. Brinker TJ, Hekler A, Enk AH, et al. A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. *Eur J Cancer*. 2019;111:148-154. doi:10.1016/j.ejca.2019.02.005.
- Brinker TJ, Hekler A, Hauschild A, et al. Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark. *Eur J Cancer*. 2019;111:30-37. doi:10.1016/j.ejca.2018.12.016.
- 8. Marka A, Carter JB, Toto E, Hassanpour S. Automated detection of nonmelanoma skin cancer using digital images: a systematic review. *BMC Med Imaging*. 2019;19(1):21. doi:10.1186/s12880-019-0307-7.
- Rajpara SM, Botello AP, Townend J, Ormerod AD. Systematic review of dermoscopy and digital dermoscopy/ artificial intelligence for the diagnosis of melanoma. *Br J Dermatol*. 2009;161(3):591-604. doi:10.1111/j.1365-2133.2009.09093.x.
- 10. Patrick MT, Raja K, Miller K, et al. Drug Repurposing Prediction for Immune-Mediated Cutaneous Diseases using a Word-Embedding-Based Machine Learning Approach. *J Invest Dermatol.* 2019;139(3):683-691. doi:10.1016/j.jid.2018.09.018.
- 11. Lee EY, Kulkarni RP. Circulating biomarkers predictive of tumor response to cancer immunotherapy. *Expert Rev Mol Diagn*. 2019;19(10):895-904. doi:10.1080/14737159.2019.1659728.
- 12. Taroni JN, Martyanov V, Mahoney JM, Whitfield ML. A Functional Genomic Meta-Analysis of Clinical Trials in Systemic Sclerosis: Toward Precision Medicine and

Combination Therapy. *J Invest Dermatol*. 2017;137(5):1033-1041. doi:10.1016/j.jid.2016.12.007.

- 13. Janda M, Soyer HP. Can clinical decision making be enhanced by artificial intelligence? *Br J Dermatol*. 2019;180(2):247-248. doi:10.1111/bjd.17110.
- 14. Wongvibulsin S, Ho BK-T, Kwatra SG. Embracing machine learning and digital health technology for precision dermatology. *J Dermatolog Treat*. 2019;154:1-2. doi:10.1080/09546634.2019.1623373.
- 15. Lim BCW, Flaherty G. Artificial intelligence in dermatology: are we there yet? *Br J Dermatol*. 2019;181(1):bjd.17899–191. doi:10.1111/bjd.17899.

Journal Prendic

